Top Markets
Coin of the day
BillionToOne, Inc. BillionToOne, Inc.

BillionToOne, Inc.

BLLN
Rank in Stocks #3874
BillionToOne, Inc. is a specialized diagnostics company that innovates by... BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Share Price
$97.36
Market Cap
$4.48B
Change (1 day)
-2.72%
Change (1 year)
-
Country
US
Trade BillionToOne, Inc. (BLLN)

Category

P/B ratio for BillionToOne, Inc. (BLLN)
P/B ratio as of 2026 TTM: 0
According to BillionToOne, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for BillionToOne, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
4.1431 -
US
2.7156 -
US
- -
CN
24.3791 -
US
5.9029 -
US